Inflammatory bowel disease, or IBD, causes chronic inflammation in the digestive tract. To find better ways to treat this condition, researchers recently created a new model of the human intestine using stem cells. Stem cells are special cells that can develop into many different tissue types, allowing scientists to recreate human intestinal tissue in the lab.
Using this new lab-grown model, the research team tested various substances and found a surprising candidate. They discovered that glycyrrhizin, a natural compound derived from black licorice, has strong anti-inflammatory properties. When tested, this compound successfully reduced the intestinal damage and cell death that are typically associated with IBD.
While these results are exciting, the research is still in its early preclinical stages. So far, the compound has only been tested in lab-grown tissues and mouse models. Scientists will need to conduct future clinical trials to confirm whether it is safe and effective for human patients.
Imagine taking a promising new cancer treatment from its basic genetic blueprint to actually dosing a patient in less than a year. That is exactly what a recent case study achieved with a highly specialized treatment called a dual-paratopic cancer immunotherapy. This type of therapy uses complex molecules, known as bifunctional antibodies, which are designed to attach to two different targets on a cancer cell at the same time. While these complex drugs offer exciting new ways to fight disease, they are notoriously difficult to manufacture and often suffer from low production yields in the laboratory.
To solve this manufacturing bottleneck, developers turned to a platform called the CHO Edge System. This system accelerates the creation of drug-producing cell lines by combining artificial intelligence with advanced genetic engineering. It relies on specially modified host cells and a "hyperactive transposase" a type of genetic tool that helps efficiently paste new instructions into a cell's DNA. By using AI to guide this genetic design, the manufacturing team was able to bypass the usual roadblocks that slow down the production of complex biologic drugs.
